Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 19, 2008

View Archived Issues

LITHE, AMBITION studies reveal efficacy of tocilizumab in rheumatoid arthritis

Novel activin receptor type IIB proven effective in murine model of ALS

Preclinical profile of sanofi-aventis' novel histamine H3 antagonist reported

Antidepressant and antipsychotic activity reported with Wyeth's WS-50030

Medgenics encouraged by preliminary results with EPODURE in phase I/II study

Single and multiple doses of PGG-glucan safe and well tolerated in phase I studies

Lundbeck reviews quarterly developments

Genzyme and the ICGEB collaborate to advance treatments for malaria and other diseases

RegeneRX's RGN-259 used under compassionate use IND in corneal ulcers

Altus to submit NDA for Trizytek in pancreatic insufficiency in the first-half of 2009

Teva and Active Biotech complete enrollment in phase III ALLEGRO clinical trial of laquinimod

New contraceptive agents reported in recent Addex patent

Institute for OneWorld Health patent discloses new agents for diarrhea

Recent Pfizer patent describes novel treatments for lipoprotein disorders

Thallion initiates enrollment in phase II trial of TLN-232 for metastatic melanoma

Neuralstem to collaborate with Albert-Ludwigs-University in neural stem cell therapies

Debiopharm and Pharmaleads sign license agreement for Debio-0827

IDM Pharma receives CHMP recommendation for approval for mifamurtide

Phase IIb bicifadine study in diabetic neuropathic pain fails to meet primary endpoint

FDA grants orphan drug status to melphalan for cutaneous and ocular melanoma

Freedom-C oral treprostinil trial in PAH fails to meet primary endpoint

IDMC recommends continuation of Novogen's phase III trial of phenoxodiol

TorreyPines licenses to QR Pharma worldwide rights to compounds for Alzheimer's disease

Proteo starts phase II trial with Elafin in patients undergoing esophagectomy

Celator enrolls first patient in phase II CPX-351 study

JUPITER study: Rosuvastatin beneficial in patients with normal cholesterol but elevated CRP

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 3, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...